Correction: Downsizing the BAD BH3 peptide to small constrained α-helices with improved ligand efficiency

Area of Science:

• Biochemistry
• Molecular Biology
• Medicinal Chemistry

Background:

• The BCL2-associated agonist of cell death (BAD) protein regulates apoptosis.
• The BH3 (Bcl-2 homology domain 3) domain of BAD is crucial for its function.
• Targeting protein-protein interactions (PPIs) is a key strategy in drug discovery.

Purpose of the Study:

• To correct and clarify the findings of a previous study on downsizing the BAD BH3 peptide.
• To investigate the development of small, constrained alpha-helical mimetics of the BAD BH3 domain.
• To improve the ligand efficiency and binding affinity of these peptide mimetics.

Main Methods:

• Peptide synthesis and structural characterization.
• Circular dichroism spectroscopy to assess helical content.
• Isothermal titration calorimetry to measure binding affinity.
• Computational modeling to understand structure-activity relationships.

Main Results:

• Successful design and synthesis of constrained alpha-helical peptides mimicking the BAD BH3 domain.
• Demonstrated improved helical stability and ligand efficiency compared to the parent peptide.
• Quantified enhanced binding affinity to BCL-xL, a key anti-apoptotic protein.

Conclusions:

• Downsizing the BAD BH3 peptide into small, constrained alpha-helices is a viable strategy for developing potent apoptosis modulators.
• These optimized helices represent promising scaffolds for novel therapeutics targeting cancer and other diseases driven by aberrant apoptosis.
• The findings provide a foundation for further development of BH3 mimetics with improved pharmacological properties.